BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee J, Cho S, Kim HJ, Lee H, Ko MJ, Lim YS. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study. J Viral Hepat 2021;28:353-63. [PMID: 33051945 DOI: 10.1111/jvh.13418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jeng WJ, Liaw YF. Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. Semin Liver Dis 2021;41:349-57. [PMID: 34182587 DOI: 10.1055/s-0041-1729973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
3 Huang ZH, Lu GY, Qiu LX, Zhong GH, Huang Y, Yao XM, Liu XH, Huang SJ, Wu T, Yuan Q, Wang YB, Su YY, Zhang J, Xia NS. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer 2022;22:287. [PMID: 35300634 DOI: 10.1186/s12885-022-09413-7] [Reference Citation Analysis]
4 Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, Gordon SC, Flaherty JF, Yee LJ, Zhao Y, Agarwal K, Lampertico P. Review: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther 2022. [PMID: 35178711 DOI: 10.1111/apt.16788] [Reference Citation Analysis]